Abstract: The present disclosure provides compositions and methods for delivery of therapeutic agents across a barrier. The compositions include a therapeutic agent (e.g., antimicrobial agent, antibiotic, or anesthetic agent), a permeation enhancer which increases the flux of the therapeutic agent across the barrier, and a matrix forming agent, wherein the composition comprises between about 0.5-5.0% wt/vol of a permeation enhancer that is sodium dodecyl sulfate; wherein the compositions comprise between about 0.5-2.5% wt/vol of a permeation enhancer that is bupivacaine; wherein the compositions comprise between about 1.5-12.0% wt/vol of a permeation enhancer that is limonene; and wherein the compositions comprise between about 9.0-19.0% wt/vol of a polymer that is poloxamer 407-poly(butoxy)phosphoester; and optionally further comprises between about 0.01-0.50% wt/vol of another therapeutic agent that is a sodium channel blocker anesthetic agent (e.g., tetrodotoxin).

Abstract: Electrical impulses are received from a beating heart. The electrical impulses are converted to an ECG waveform. The ECG waveform is converted to a frequency domain waveform, which, in turn, is separated into two or more different frequency domain waveforms, which, in turn, are converted into a plurality of time domain cardiac electrophysiological subwaveforms and discontinuity points between these subwaveforms. The plurality of subwaveforms and discontinuity points are compared to a database of subwaveforms and discontinuity points for normal and abnormal patients or to a set of rules developed from the database. An ST segment and one or more ST subwaveforms within the ST segment are identified from the plurality of subwaveforms and discontinuity points based on the comparison. The ECG waveform with the one or more ST subwaveforms within the ST segment is displayed.

Abstract: The present invention provides compositions and methods for delivery of therapeutic agents across an barrier. The compositions include a therapeutic agent (e.g., antimicrobial agent, antibiotic, or anesthetic agent), a permeation enhancer which increases the flux of the therapeutic agent across the barrier, and a matrix forming agent. The matrix forming agent forms a gel at a suitable gelation temperature and rheological properties for use in drug delivery, and in some cases, the gelation temperature and rheological properties are not significantly changed from those of the composition without the permeation enhancer. The invention also provides a matrix forming agent and compositions thereof. Such compositions are particularly useful in the treatment of otitis media. Methods of treatment, methods of delivery, and kits for the compositions described herein are also provided.

Abstract: A composition for use in the treatment of ocular hyperemia includes an anti-angiogenic agent and an ? adrenergic receptor agonist. A method for treating ocular hyperemia for a patient includes inhibiting a plurality of kinase receptors of the patient with an MKI; and activating ? adrenergic receptor of the patient with an agonist of the receptor.

Abstract: This disclosure relates to pharmaceutical chemistry, and more particularly to a metalloporphyrin compound, and a preparation and application thereof. The metalloporphyrin compound is shown in formula (I), or an optical isomer, a pharmaceutically-acceptable salt or a solvate thereof, and can specifically recognize the HIV RNA and effectively inhibit HIV reverse transcriptase. This disclosure also provides uses of the compound in the preparation of a reagent for selectively recognizing HIV TAR RNA and a HIV reverse transcriptase inhibitor.

Abstract: A pressure relief arrangement for a gas turbine engine comprises a hinged door and a mount. A plastically deformable member is provided between and coupled to the hinged door and the mount. The deformable member is configured to deform between a non-deformed state when the door is in a closed position and an elongated deformed state when the door is in an open position.

Abstract: Embodiments of this application disclose a congestion control method and a related device. A Transmission Control Protocol offload engine TOE sends a congestion control notification to a central processing unit CPU, where the congestion control notification instructs the CPU to obtain a target parameter, and the target parameter is used by the CPU to generate a congestion control calculation result. The TOE obtains the congestion control calculation result returned by the CPU, where the congestion control calculation result includes a congestion control window value. The TOE sends a packet based on the congestion control window value. In this application, the TOE and the CPU implement congestion control together. When a new congestion control algorithm emerges, the new congestion control algorithm may be applied without changing a structure of the TOE. Therefore, in this application, an upgrade period of the congestion control algorithm can be shortened, and flexibility can be improved.

Abstract: A method for treating an eye disease of an affected eye includes administering to the affected eye of a subject in need of such treatment a steroidal-androgen-free composition containing a therapeutically effective amount of beta-cyclodextrin derivative. The eye disease can be meibomian gland dysfunction, blepharitis, or dry eye disease. A steroidal-androgen-free composition includes a beta-cyclodextrin derivative as a sole active pharmaceutical ingredient. The steroidal-androgen-free composition is an ophthalmic composition.

Abstract: A system and method for optimization of on-demand microtransit is provided. A list of possible stops of one or more vehicles is maintained. A plurality of requests for transportation are received, each of the requests associated with at least one traveler. Travelers to be transported by one of the vehicles are selected. A set of a minimal number of the stops is selected, the set comprising at least one stop that is within a predefined walking distance of the origin location of each of the selected travelers and at least one stop within the predefined walking distance of the destination location of each of the selected travelers. Potential routes are identified for the vehicle that include the stops in the set. The potential routes are evaluated using a plurality of constraints and one of the routes is selected for fulfilling the requests of the selected travelers.

Abstract: A method for treating an eye disease of an affected eye includes administering to the affected eye of a subject in need of such treatment a steroidal-androgen-free composition containing a therapeutically effective amount of beta-cyclodextrin derivative. The eye disease can be meibomian gland dysfunction, blepharitis, or dry eye disease. A steroidal-androgen-free composition includes a beta-cyclodextrin derivative as a sole active pharmaceutical ingredient. The steroidal-androgen-free composition is an ophthalmic composition.

Abstract: The present invention relates to carbon nanotubes and a preparation method thereof by using PET. The carbon nanotubes of the present invention are prepared by processes of alcoholysis of PET materials, processes of washing, crushing and calcining unreacted intermediates and so on. By the preparation method of the present invention, multi-walled carbon nanotubes prepared by using waste PET have a good conductivity, and are a structure of top-down array with low aspect ratio. The method of the present invention is not only easy to implement, but also does not need a catalyst, and turns the waste PET into treasure, which solves the problem of environmental pollution caused by the increasingly serious waste PET. FIG. 9.

Abstract: A method of producing synergistic and enhanced efficacy in treating a disease in a subject includes providing an antibody, the antibody being a classic antibody or a modified biologic molecule that blocks a first target in the subject; providing a drug, the drug being a small molecule agent that blocks the first target or a second target in the subject; connecting the antibody and the drug with a linker to form an Antibody-Drug Synergism (ADS) compound; and treating the disease with the ADS compound. The linker is hydrolyzed in the subject over a certain time so that both the antibody and the drug exert their functions simultaneously, and the ADS compound confers better efficacy than either the antibody or the drug alone due to a synergism of the ADS compound.

Abstract: A method for treating a meibomian gland dysfunction of an affected eye includes administering to the affected eye of a subject in need of such treatment a steroidal-androgen-free composition containing a therapeutically effective amount of a cyclic polysaccharide. A steroidal-androgen-free composition includes a cyclic polysaccharide as an active pharmaceutical ingredient for treating a meibomian gland dysfunction of an affected eye.

Abstract: A method of producing synergistic and enhanced efficacy in treating a disease in a subject includes providing an antibody, the antibody being a classic antibody or a modified biologic molecule that blocks a first target in the subject; providing a drug, the drug being a small molecule agent that blocks the first target or a second target in the subject; connecting the antibody and the drug with a linker to form an Antibody-Drug Synergism (ADS) compound; and treating the disease with the ADS compound. The linker is hydrolyzed in the subject over a certain time so that both the antibody and the drug exert their functions simultaneously, and the ADS compound confers better efficacy than either the antibody or the drug alone due to a synergism of the ADS compound.

Abstract: Compositions and methods of using nintedanib for treating indications with abnormal neovascularization in the front part of the eye are disclosed.

Abstract: There is provided a method of manufacturing a semiconductor device by processing a substrate, which includes: embedding a polymer having a urea bond in a recess formed in the substrate by supplying a material for polymerization from above a sacrificial film to the substrate and forming a polymer film made of the polymer having the urea bond, wherein a surface of the substrate is covered with the sacrificial film, the recess including an opening of the sacrificial film that is formed by a patterning; removing the polymer film formed on the sacrificial film while leaving the polymer embedded in the recess; removing the sacrificial film in a state in which the polymer is embedded in the recess; and subsequently, removing the polymer embedded in the recess.

Abstract: A method for treating a meibomian gland dysfunction of an affected eye includes administering to the affected eye of a subject in need of such treatment a steroidal-androgen-free composition containing a therapeutically effective amount of a cyclic polysaccharide. A steroidal-androgen-free composition includes a cyclic polysaccharide as an active pharmaceutical ingredient for treating a meibomian gland dysfunction of an affected eye.

Abstract: A mount structure for mounting an ancillary engine unit to a gas turbine engine is provided. The mount structure has plural elongate struts which each extend from a connector portion at one end of the strut to a fastening portion at the other end of the strut. The housing of the ancillary engine unit is formed of a first material having a first coefficient of thermal expansion, and the elongate struts are formed of a second material having a second coefficient of thermal expansion. Each elongate strut extends away from its connector portion in a direction which is crosswise to the direction of the hypothetical differential thermal strain at that connector portion. The mount structure further has a containment bracket which is configured to contain each connector portion.

Abstract: The disclosure provides a method and an apparatus for controlling ZigBee® sensors. The method comprises: selecting a second coordinator of a second ZigBee® network as a backup coordinator; detecting whether there is a failure of a first ZigBee® coordinator; and if a failure of the working coordinator is detected, designating the second ZigBee® coordinator as the networking coordinator for the end user devices in the first ZigBee® network to join the second ZigBee® network.

Abstract: Compositions and methods of using nintedanib for improving the success rate of glaucoma filtration surgery are disclosed herein. Nintedanib can be used alone or in combination with an anti-metabolite drug in a topical or implant eye formulation.